Captor Therapeutics, a biopharmaceutical company specialized in the development of drugs based on Targeted Protein Degradation (TPD), on 07.05.2024 signed an agreement for realisation and co-funding for the second phase of its project CT-03 entitled: “Inducing apoptosis with small molecules as therapeutic intervention in multiple severe malignancies – II phase”. The Agreement approves the extension of the project until 31.07.2026.
CT-03 is one of the most advanced projects run by Captor, the Company specialized in the Targeted Protein Degradation Therapy.
The main goal of the project is to discover and develop a novel drug candidate for MCL-1 by molecular inductive protein degradation. Trageted Protein Degradation is a novel approach, which through Captors bifunctional degraders cause a massive apoptosis in cancer cells and ultimately could be used for severe incurable diseases with high unmet medical needs, including haematological, breast and lung cancers.
In the IV quarter of 2023 Captor published promising toxicological and pharamcokinetic results with proven effectiveness in animal model and cancer cell lines isolated from patients with leukemia.
All data collected allow us to assume that an application for Clinical Trial will be submitted in 2024.
Total Project Value: 35 902 013,75 PLN
II phase value: 7 802 294,00 PLN
II phase funding: 4 976 940,75 PLN
II phase timeline: 01.01.2024 – 31.07.2026
The signing of the agreement will enable financing of the unfinished phase of research in the next financing cycle from European Union funds. Thanks to this, the company has a chance to enter more advanced stages of the project. As part of Phase II, Captor planned the selection of a clinical candidate, further research on its safety, large-scale synthesis and initiation of clinical trials.
